小智港股覆盤 | 1月10日
今日，港股三大指數集體下跌。截止收盤，恆生指數跌0.27%，報21331點。國企指數跌0.31%，報7263點。恆生科技指數跌0.27%，報4558點。市場約703只個股上漲，942只個股下跌。成交額突破1313.56億港幣，和昨天同期相比下跌16.03%。南下資金淨流出575.43萬港幣。
盤面上，汽車板塊集體拉昇。理想汽車-W、蔚來-SW、吉利汽車等多股漲超6%；小鵬汽車-W漲超4%；長城汽車漲超3%。招商證券(香港)：維持理想汽車-W“增持”評級，目標價128港元；蔚來-SW升8%領跑板塊，機構指新能源車行業估值體系面臨重構；交銀國際重申吉利汽車買入評級，目標價21.5港元；長城汽車：2022年12月1日至12月31日共有1000元“長汽轉債”轉股。
綜合金融服務板塊大漲靠前。百應控股漲超10%；友聯租賃漲超8%；鼎億集團投資、山高控股等多股漲超7%；海通恆信漲超5%。友聯租賃漲1.10%，現報11.78元，創52周新高；山高控股現漲近5%，附屬與中國電建集團及山東路橋訂立兩份總工程合同。
互聯網醫療板塊走高。阿裏健康漲超3%。恆生指數收漲3.22%報20793點，內房物業、互聯網醫療板塊走高，阿裏健康漲11.28%。
娛樂板塊走低。新娛科控股跌超25%；傳遞娛樂跌超8%；騰訊音樂-SW跌超7%；英皇文化產業、A8新媒體等多股跌超6%。A8新媒體因購股權獲行使發行50萬股。
貿易經銷板塊走弱。集一控股(舊)跌超17%；大豐港跌超15%；昊天國際建投、太和控股等多股跌超10%；新源萬恆控股跌超7%。
生物科技板塊走弱。中生北控生物科技跌超19%；再鼎醫藥跌超10%；聯康生物科技集團跌超7%；康方生物-B、東曜藥業-B等多股跌超2%。再鼎醫藥跳空高開14.86%，治療肺癌藥研究達主要終點總生存期。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
